Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04053803
PHASE2

An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia

Sponsor: Imara, Inc.

View on ClinicalTrials.gov

Summary

This is an open-label extension study of IMR-687 in adult patients who completed Imara's blinded Phase 2a study (IMR-SCD-102). The open-label extension study will evaluate long-term safety and tolerability.

Official title: An Open-label Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia) Who Participated in Study IMR-SCD-102

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2019-05-22

Completion Date

2025-03

Last Updated

2022-03-04

Healthy Volunteers

No

Interventions

DRUG

IMR-687

Oral administration of once daily IMR-687

Locations (7)

University of Connecticut Health Center

Farmington, Connecticut, United States

Foundation for Sickle Cell Disease Research

Hollywood, Florida, United States

Baylor Scott & White Medical Center - Temple

Temple, Texas, United States

Bristol Haematology and Oncology Centre

Bristol, United Kingdom

University College London Hospital NHS Foundation Trust

London, United Kingdom

Guy's and St Thomas Hospital CRF

London, United Kingdom

Royal London Hospital

London, United Kingdom